4,333 Shares in Cencora, Inc. (NYSE:COR) Purchased by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P acquired a new stake in shares of Cencora, Inc. (NYSE:COR) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 4,333 shares of the company’s stock, valued at approximately $974,000.

A number of other hedge funds also recently bought and sold shares of the business. United Bank increased its holdings in shares of Cencora by 4.2% in the third quarter. United Bank now owns 5,601 shares of the company’s stock valued at $1,261,000 after purchasing an additional 225 shares during the last quarter. CreativeOne Wealth LLC purchased a new stake in Cencora in the 3rd quarter valued at $1,212,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Cencora by 3.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 90,767 shares of the company’s stock worth $20,430,000 after acquiring an additional 2,711 shares during the last quarter. Public Sector Pension Investment Board raised its holdings in shares of Cencora by 53.2% during the 3rd quarter. Public Sector Pension Investment Board now owns 6,908 shares of the company’s stock worth $1,555,000 after acquiring an additional 2,400 shares during the period. Finally, Financial Counselors Inc. raised its holdings in shares of Cencora by 20.2% during the 3rd quarter. Financial Counselors Inc. now owns 1,284 shares of the company’s stock worth $289,000 after acquiring an additional 216 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of COR stock opened at $275.16 on Friday. The firm has a 50 day moving average of $253.81 and a two-hundred day moving average of $241.21. The stock has a market capitalization of $53.36 billion, a PE ratio of 39.14, a P/E/G ratio of 1.31 and a beta of 0.51. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $275.57.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.80%. Cencora’s dividend payout ratio is currently 31.29%.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Mizuho started coverage on shares of Cencora in a report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target for the company. Wells Fargo & Company lifted their target price on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research report on Friday, March 14th. JPMorgan Chase & Co. increased their price target on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Evercore ISI boosted their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Finally, StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $280.20.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the sale, the chairman now directly owns 317,913 shares of the company’s stock, valued at approximately $85,680,732.63. The trade was a 4.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,675 shares of company stock worth $8,034,778 in the last 90 days. Corporate insiders own 10.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.